

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

**PROPOSED ADOPTION OF THE TENTH AMENDED
AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company hereby announces that, on the date of this announcement, resolutions have been passed to propose to amend the existing ninth amended and restated memorandum and articles of association of the Company (“**M&AA**”) and to adopt the tenth amended and restated M&AA primarily to bring the M&AA in line with the amendments made to Appendix 3 to the Listing Rules which took effect on January 1, 2022 (the “**Proposed Amendments**”).

Major changes brought about by the Proposed Amendments are set out below:

1. to provide that the Company shall hold a general meeting as its annual general meeting within six months after the end of each financial year;
2. to provide that shareholders of the Company (the “**Shareholders**”) shall have the right to speak and vote at a general meeting of the Company unless such Shareholder is required by the Listing Rules to abstain from voting to approve the matter under consideration;
3. to provide that a meeting of the Shareholders may be held by means of such telephone, electronic or other communication facilities as permit all persons participating in the meeting to communicate with each other simultaneously and instantaneously;
4. to provide that a recognized clearing house, as a Shareholder, may authorize such person(s) as it thinks fit to act as its representative(s) at any general meeting of the Company or any creditors meeting of the Company and such person(s) so authorized shall be entitled to exercise the same rights and powers on behalf of the recognized clearing house;
5. to provide that the appointment, removal and remuneration of auditors must be approved by a majority of the Shareholders;

6. to provide that subject to the Companies Act the Company may by a special resolution resolve that the Company be wound up voluntarily; and
7. to make other housekeeping amendments to update or clarify provisions where it is considered desirable.

The Proposed Amendments are subject to the approval of the Shareholders by way of a special resolution to be considered and, if thought fit, passed at the forthcoming annual general meeting of the Company (the “AGM”). The tenth amended and restated M&AA will become effective upon the approval by the Shareholders at the AGM.

A circular containing, among other matters, details of the proposed adoption of the tenth amended and restated M&AA, together with a notice of the AGM are expected to be despatched to the Shareholders in April 2023.

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, December 14, 2022

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.